A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

  • Cancer
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • Aalborg
  • Aarhus
  • Adelaide
  • AEB
  • Ahmedabad
  • Amsterdam
  • Arezzo
  • Athens
  • Badalona
  • Baia Mare
  • Barcelona
  • Bari
  • Barrie
  • Basel
  • Bayrut
  • Bellinzona
  • Bergamo
  • Bern
  • Bilbo
  • Bogotá
  • Bologna
  • Box Hill
  • Braga
  • Bratislavský kraj
  • Bruxelles
  • Budapest
  • Buenos Aires
  • Calgary
  • Cardiff
  • Catania
  • Ceará
  • Chieti
  • Chur
  • Cluj-Napoca
  • Coimbra
  • Cork
  • Craiova
  • Cremona
  • Cáceres
  • Córdoba
  • Dresden
  • Edmonton
  • Erlangen
  • Florești
  • Garran
  • Genoa
  • Genève
  • Girona
  • Groningen
  • Guadalajara
  • Gurugram
  • Göttingen
  • Halifax
  • Halle (Saale)
  • Hannover
  • Heidelberg
  • Herlev
  • Hlavní město Praha
  • Hobart
  • Innsbruck
  • Inverness
  • Jette
  • Jihomoravský kraj
  • Kaunas
  • Kifisia
  • Kolkata
  • København
  • L'Hospitalet de Llobregat
  • Leicester
  • Leuven
  • Linz
  • Lisboa
  • Lombardia
  • London
  • Lublin
  • Lugo
  • luik
  • Luzern 16
  • Lübeck
  • Maastricht
  • Macquarie University
  • Madrid
  • Manresa
  • Meldola
  • Milano
  • Modena
  • monserrato
  • Moscow
  • Moskva
  • Murcia
  • Málaga
  • Mönchengladbach
  • München
  • Münster
  • nan-jing-shi
  • Napoli
  • New Delhi
  • Ottawa
  • Ourense
  • Oviedo
  • Padova
  • Palma
  • Pamplona
  • Paraná
  • Pireas
  • Pisa
  • Plovdiv
  • Porto
  • Poznań
  • Randwick
  • Reggio Emilia
  • Rio Grande do Sul
  • Riyadh
  • Roma
  • Sabadell
  • Salzburg
  • San Cristóbal de La Laguna
  • San Giovanni Rotondo
  • Sanatorio San Luigi
  • Santiago de Compostela
  • Sevilla
  • Sofia
  • South Brisbane
  • St Leonards
  • Sutton
  • Szeged
  • Szolnok
  • São Paulo
  • Tainan City
  • Tallinn
  • Taoyuan City
  • Terni
  • Thermi
  • Thessaloniki
  • Timișoara
  • Toledo
  • Tübingen
  • Udine
  • Ulm
  • Utrecht
  • València
  • Verona
  • Vilnius
  • Waratah
  • Warszawa
  • Wien
  • Winterthur
  • Zagreb
  • Żory
  • София
Trial Identifier:

NCT02928406 2016-002625-11 MO29983

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02928406 , MO29983 , 2016-002625-11 Trial Identifier
      Atezolizumab Treatments
      Urinary Tract Cancer Condition
      Official Title

      An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
      • Participants with measurable and/or non-measurable disease according to RECIST v1.1
      • Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
      • If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
      • Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
      Exclusion Criteria
      • Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
      • Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation

      1. Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible

      2. Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible

      • Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
      • Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
      • Significant renal disorder indicating a need for renal transplant

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now